Filing Details

Accession Number:
0001225208-12-016839
Form Type:
4
Zero Holdings:
No
Publication Time:
2012-07-30 17:46:35
Reporting Period:
2012-07-26
Filing Date:
2012-07-30
Accepted Time:
2012-07-30 17:46:35
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1099800 Edwards Lifesciences Corp EW Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842) 364316614
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1346974 M Thomas Abate One Edwards Way
Irvine CA 92614
Cvp, Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2012-07-26 45,000 $21.96 91,474 No 4 M Direct
Common Stock Disposition 2012-07-26 1,900 $104.04 89,574 No 4 S Direct
Common Stock Disposition 2012-07-26 8,060 $101.14 81,514 No 4 S Direct
Common Stock Disposition 2012-07-26 11,491 $102.98 70,023 No 4 S Direct
Common Stock Disposition 2012-07-26 23,549 $102.33 46,474 No 4 S Direct
Common Stock Acquisiton 2012-07-27 15,000 $21.50 61,474 No 4 M Direct
Common Stock Disposition 2012-07-27 1,000 $103.16 60,474 No 4 S Direct
Common Stock Disposition 2012-07-27 2,800 $103.99 57,674 No 4 S Direct
Common Stock Disposition 2012-07-27 11,200 $105.27 46,474 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Employee Stock Option (Right to Acquire) Disposition 2012-07-26 45,000 $0.00 45,000 $21.96
Common Stock Employee Stock Option (Right to Acquire) Disposition 2012-07-27 15,000 $0.00 15,000 $21.50
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
47,000 2007-05-11 2013-05-10 No 4 M Direct
20,000 2007-02-15 2013-02-15 No 4 M Direct
Footnotes
  1. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person. This amount includes quarterly acquisition of shares under the Edwards Lifesciences Corporation Employee Stock Purchase Plan as reflected on the most recent report of the plan administrator.
  2. This transaction was executed in multiple trades at prices ranging from $103.74 to $104.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  3. This transaction was executed in multiple trades at prices ranging from $100.61 to $101.59. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  4. This transaction was executed in multiple trades at prices ranging from $102.62 to $103.53. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  5. This transaction was executed in multiple trades at prices ranging from $101.62 to $102.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  6. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 31, 2012.
  7. This transaction was executed in multiple trades at prices ranging from $103.67 to $104.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  8. This transaction was executed in multiple trades at prices ranging from $104.77 to $105.74. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
  9. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the reporting person.